NANX (NANX)

OTC Markets
Currency in USD
3.4000
+0.0400(+1.19%)
Delayed Data·
Showing NANX historical data. For real-time data please try another search
Day's Range
3.06723.4700
52 wk Range
1.210016.5600
Key Statistics
Edit
Prev. Close
1.84
Open
3.33
Day's Range
3.0672-3.47
52 wk Range
1.21-16.56
Volume
81.95K
Average Volume (3m)
120.4K
1-Year Change
128.19%
Book Value / Share
-
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock

NANX News & Analysis

Show more

NANX Company Profile

Solesence, Inc., a science-driven company, develops, manufactures, and sells integrated family of technologies in the United States. The company engages in engineered materials, formulation development, and commercial manufacturing. It also provides skin care formulations with mineral-based UV protection enabled by proprietary active pharmaceutical ingredients under the Solésence brand; skin health products, such as sunscreens and daily care products; and advanced material products, including architectural coatings, industrial coatings, abrasion-resistant additives, plastics additives, and medical diagnostics applications. The company was formerly known as Nanophase Technologies Corporation and changed its name to Solesence, Inc. in March 2025. Solesence, Inc. was incorporated in 1989 and is headquartered in Romeoville, Illinois.

NANX Earnings Call Summary for Q4/2024

  • Q4 2024 revenue up 57% YoY to $12.6M; full-year revenue reached $52.3M, a 40% increase. Gross margin expanded to 22% in Q4 from 6% last year.
  • Net loss narrowed to $600K from $2.1M YoY. Full-year net income of $4.2M, compared to $4.4M loss in 2023. Stock price rose 1.97% post-earnings.
  • Over two dozen new products launched and two patents received. Company targets 30%+ growth in 2025 with 30-40% gross margins.
  • Plans for NASDAQ uplisting in 2025 announced. Search for dedicated CFO underway to support expansion efforts.
  • Cautious about tariff impacts and conservative customer ordering patterns. Anticipates record revenues in Q1 2025 and strong Q2 performance.
Last Updated: 2025-03-27, 09:20 a/m
Read Full Transcript

Earnings

Latest Release
Mar 31, 2025
EPS / Forecast
-0.01 / --
Revenue / Forecast
12.57M / --
EPS Revisions
Last 90 days

NANX Income Statement

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2025 - Fusion Media Limited. All Rights Reserved.